Spring Bank Pharmaceuticals, Inc. (SBPH) News

Spring Bank Pharmaceuticals, Inc. (SBPH): $4.84

0.00 (0.00%)

POWR Rating

Component Grades








Add SBPH to Watchlist
Sign Up

Industry: Medical - Pharmaceuticals




in industry

Filter SBPH News Items

SBPH News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest SBPH News From Around the Web

Below are the latest news stories about Spring Bank Pharmaceuticals Inc that investors may wish to consider to help them evaluate SBPH as an investment opportunity.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Spring Bank Pharmaceuticals, Inc.

NEW YORK, Sept. 22, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Spring Bank Pharmaceuticals, Inc. ("SBPH" or the "Company") (NASDAQ: SBPH) in connection with SBPH's July 29, 2020 merger and…

PR Newswire | September 22, 2020

ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm - SBPH, VAR, JCAP, GLIBA

NEW YORK, Sept. 3, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its…

PR Newswire | September 3, 2020

NASDAQ listing expected as F-star Therapeutics announces merger with Spring Bank Pharmaceuticals

The combined company will be headquartered at Babraham Research Campus and in Cambridge, Massachusetts.

Cambridge Independent | August 3, 2020

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Spring Bank Pharmaceuticals, Inc.

Rowley Law PLLC is investigating potential securities law violations by Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) and its board of directors concerning the proposed merger of the company with F-star Therapeutics, Limited. Spring Bank Pharmaceuticals stockholders will own approximately 38.8% of the combined company. The transaction is expected to close in late 2020.

Yahoo | July 31, 2020

Spring Bank Pharma to merge with F-Star Therapeutics in all-stock deal

In a reverse merger aimed at a Nasdaq listing, privately held F-star Therapeutics will combine with Spring Bank Pharmaceuticals ([[SBPH]] -10.1%). The new organization will do business under the F-star monikerCurrent Spring Bank and F-star equity holders will own ~38.8% and 61.2%, respectively, of the combined company.The new firm will focus...

Seeking Alpha | July 30, 2020

SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Spring Bank Pharmaceuticals, Inc. (NasdaqGS - SBPH)

BALA CYNWYD, PA / ACCESSWIRE July 30, 2020 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Spring Bank Pharmaceuticals, Inc.

Yahoo | July 30, 2020

The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) * Abbott Laboratories (NYSE: ABT) * ABIOMED, Inc. (NASDAQ: ABMD) * Adamis Pharmaceuticals Corp (NASDAQ: ADMP) * Annexon Inc (NASDAQ: ANNX) (went public Friday) * Bio-Rad Laboratories, Inc. Class B (NYSE: BIO-B) * Hologic, Inc. (NASDAQ: HOLX) * Intuitive Surgical, Inc. (NASDAQ: ISRG) * ITAMAR MED LTD/S ADR (NASDAQ: ITMR) * Merit Medical Systems, Inc. (NASDAQ: MMSI) * NeoGenomics, Inc. (NASDAQ: NEO) * Novavax, Inc. (NASDAQ: NVAX) * OncoSec Medical Inc (NASDAQ: ONCS) * Paratek Pharmaceuticals Inc (NASDAQ: PRTK) (moved on rumors of a BARDA loan) * Penumbra Inc (NYSE: PEN) * Qiagen NV (NYSE: QGEN) * Zoetis Inc (NYSE: ZTS)Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 29) * Forma Therapeutics Holdin...

Yahoo | July 30, 2020

Spring Bank Pharmaceuticals and F-star Therapeutics Agree to Combine to Pursue Mission of Creating Next Generation Immunotherapies

* Combined company will operate as F-star Therapeutics and advance pipeline of multiple clinical-stage immuno-oncology programs * Combined company expected to have at least $40 million in cash prior to closing * Spring Bank stockholders to receive two separate contingent value rights related to Spring Bank’s STING agonist and STING antagonist programs * Companies to host joint conference call on July 30, 2020 at 7:30 a.m. Eastern Time HOPKINTON, Mass. and CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 29, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, and F-star Therapeutics, Limited (“F-star”), a privately-held clinical...

Yahoo | July 29, 2020

Hedge Funds Are Selling Spring Bank Pharmaceuticals, Inc. (SBPH)

In this article we will check out the progression of hedge fund sentiment towards Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 […]

Yahoo | June 5, 2020

Spring Bank Pharmaceuticals (SBPH) Investor Presentation - Slideshow

The following slide deck was published by Spring Bank Pharmaceuticals, Inc. in conjunction with this event....

SA Transcripts | June 3, 2020

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!